Longevity & Aging

Investigational Drug Z-Basivarsen Shows Sustained Strength and Function Gains in Myotonic Dystrophy

Myotonic dystrophy type 1 (DM1) is a progressive genetic muscle disease with no approved disease-modifying treatment. New data from the ACHIEVE trial suggest that z-basivarsen, an investigational antisense drug, meaningfully improves muscle function and strength in adults with DM1. Over 12 months, 26 patients showed sustained reductions in hand myotonia, better sit-to-stand performance, and improved muscle strength scores compared to untreated patients following the natural disease course. The drug works by targeting toxic RNA buildup caused by a DMPK gene mutation that disrupts normal protein production in muscle. Safety appeared acceptable, with no serious drug-related adverse events. While still in early-phase trials, these findings represent a potentially significant step toward a first-ever disease-modifying therapy for a condition that typically robs adults in their prime of muscle control and functional independence.